Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Editors’ Picks >>  Global CGRP Drug Market Expected to Reach USD 5 Billion by 2024

Global CGRP Drug Market Expected to Reach USD 5 Billion by 2024

October 09, 2018 By 1℃

Teva’s important asset—the migraine drug anti-CGRP antibody: AJOVYTM (fremanezumab-vfrm) was eventually marketed on September 14, 2018 after experiencing turbulence, to become the world’s 2nd anti-CGRP antibody approved for marketing, which has a more flexible way of drug use, and is priced comparably to the relevant drug of Amgen/Novartis. Refer to FDA Approved the Second Anti-CGRP New Drug for Migraine: Ajovy, with the Third One on the Way for the details. There are currently 7 noteworthy CGRP targeted drugs in the world. According to the forecast of EvaluatePharma, the global CGRP drug market will reach USD 5 billion by 2024, with 4 anti-CGRP antibodies ranking top 4 of the market. Here, this article mainly compares the clinical data of those 7 CGRP drugs, and forecasts the market size of CGRP drugs in the next 5 years.

Migraine has caused serious mental burden to patients, and anti-CGRP antibody is a class of drugs with quite definite mechanism of action therefor. There are currently 2 anti-CGRP antibody drugs marketed in CGRP drug market:

1. Aimovig (erenumab) of Amgen/Novartis was approved for marketing in May 2018, which became the first-in-class anti-CGRP monoclonal antibody drug, and is one of the high-profile drugs in 2018, with the price of USD 6,900/year.

2. Teva filed the marketing application for the anti-CGRP antibody: fremanezumab early in August 2017, and it used a priority review voucher, in the hope of ensuring fremanezumab to become the 2nd anti-CGRP antibody drug approved. The bug of Celltrion wasted the priority review voucher, however, fremanezumab was eventually marketed.

3. Furthermore, the anti-CGRP antibody: Emgality (galcanezumab) of Eli Lilly has been filed the marketing application, which may be approved for marketing on October 10, 2018 according to my forecast as per the review period of FDA.

Besides the above drugs marketed/filed for marketing, eptinezumab, rimegepant and ubrogepant, etc. are at the late clinical stages, and will be marketed successively in the future. Refer to the following table for the details:

Pharmaceutical product

Type

Company

Stage

Aimovig

(erenumab)

Antibody

Amgen/Novartis

Approved for marketing

AJOVY

(fremanezumab)

Antibody

Teva

Approved for marketing

Emgality

(Galcanezumab)

Antibody

Eli Lilly

Filed marketing application

Eptinezumab

Antibody

Alder

Phase III clinical trial

Atogepant

Small molecule

Allergan

Merck

Phase II/III clinical trial

Rimegepant

Small molecule

Bristol-Myers Squibb

Biohaven

Phase III clinical trial

Ubrogepant

Small molecule

Allergan

Merck

Phase III clinical trial

Small molecule drug vs Antibody drug:

Companies have successively published their key clinical data in the development of pharmaceutical products, which are summarized and compared here:

Drug

Company

Indication

Effectiveness VS placebo

Status

Aimovig

Amgen/Novartis

Episodic/chronic migraine

Episodic: -1.1 days

Episodic: -1.4 to -1.9 days

Marketed

AJOVY

Teva

Episodic/chronic migraine

Episodic: -1.5 days

Chronic: -2.1 days

Marketed

Emgality

Eli Lilly

Episodic/chronic migraine

Episodic: -1.8 to -1.9 days

Episodic: -1.9 to -2.0 days

Chronic: -2.0 days

PDUFA

10 Oct. 2018

eptinezumab  

Alder

Episodic/chronic migraine

Episodic: -0.7 to -1.1 days

Chronic: -2.7 days

BLA

H2 2018

Rimegepant

Biohaven

Episodic/chronic migraine

75mg dose: -2h

Pain relief rate: 19.2% vs 14.2%

 

Phase III 

Ubrogepant  

 

Allergan

Episodic/chronic migraine

50mg dose: -2h

Pain relief rate: 21.8% VS 14.3%

NDA

H1 2019

Atogepant

Allergan

Episodic/chronic migraine

Episodic: 10mg, -1.1 days

Phase III 

References: Evaluate Pharma, and official websites of companies

It can be seen that:

1.     The antibody drugs are generally administered once monthly through IV; small molecule drugs are taken orally and daily;

2.     Efficacy of antibody drugs does not differ much; efficacy of small molecule drugs is also comparable;

3.     Marketing sequence of a drug is crucial to its market share in the future.

According to the forecast of EvaluatePharma, size of the CGRP drug market will steadily grow from 2018 to 2024, and relevant antibody drugs will occupy the vast majority of the market share.

Forecast of Sales Data of CGRP Drug Market in 2018-2024:

Forecast of Sales Data of CGRP Drug Market

CGRP市场销售数据预测

(亿美金)

Forecast of Sales Data of CGRP Drug Market

(USD 100 million)

Reference: EvaluatePharma

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

 

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
web对话
live chat
客服对话